OLAGACT
DEAD

Serial Number

90779965

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Jun 17, 2021

Add to watchlist:

No watchlists yet
View on USPTO

OLAGACT Trademark

Serial Number: 90779965

OLAGACT is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on June 17, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

June 17, 2021

Registration Date

Not Registered

Published for Opposition

September 27, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use in the nature of monoclonal antibodies for medical purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 22, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 22, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 15, 2025 EXRA
SOU EXTENSION 5 GRANTED
Oct 14, 2025 EX5G
SOU TEAS EXTENSION RECEIVED
May 5, 2025 EEXT
SOU EXTENSION 5 FILED
May 4, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2024 EXRA
SOU EXTENSION 4 GRANTED
Nov 7, 2024 EX4G
SOU EXTENSION 4 FILED
Nov 7, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 7, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 6, 2024 EXRA
SOU EXTENSION 3 GRANTED
Apr 5, 2024 EX3G
SOU EXTENSION 3 FILED
Apr 5, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 5, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 30, 2023 EXRA
SOU EXTENSION 2 GRANTED
Nov 29, 2023 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 29, 2023 AITU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 21, 2023 EXRA
SOU EXTENSION 2 FILED
Nov 17, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 17, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 2, 2023 EXRA
SOU EXTENSION 1 GRANTED
Apr 28, 2023 EX1G
SOU EXTENSION 1 FILED
Apr 28, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 28, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 22, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Sep 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 19, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 19, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 19, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 19, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 19, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 12, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 12, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 15, 2022 GNRN
NON-FINAL ACTION E-MAILED
Feb 15, 2022 GNRT
NON-FINAL ACTION WRITTEN
Feb 15, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 10, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 3, 2021 NWOS
NEW APPLICATION ENTERED
Jun 21, 2021 NWAP